Glofitamab Treatment for DLBCL Shows Cost Savings Over Epcoritamab in US Healthcare
An economic model reveals glofitamab offers DLBCL patient cost savings versus epcoritamab, despite higher adverse event and treatment administration costs.
Browsing Tag
NIH
Revolutionary Method Improves Influenza Case Count in Healthcare
TL/DR -
A study suggests that the traditional definition of health care-associated influenza results in a…